Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/28/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Pfizer (PFE) Tops Q4 EPS by 8c, Beats on Revenue; Offers FY26 Guidance
February 3, 2026 6:46 AM ESTPfizer (NYSE: PFE) reported Q4 EPS of $0.66, $0.08 better than the analyst estimate of $0.58. Revenue for the quarter came in at $17.58 billion versus the consensus estimate of $16.91 billion.
GUIDANCE:
Pfizer sees FY2026 EPS of $2.80-$3.00, versus the consensus of $2.97. Pfizer sees... More
